<DOC>
	<DOCNO>NCT01798667</DOCNO>
	<brief_summary>This study design evaluate efficacy safety DA-8031 decide optimal dose DA-8031 male patient premature ejaculation oral administration on-demand . The investigator hypothesize newly-developed DA-8031 would effect delay ejaculation patient premature ejaculation ( PE ) . Design : Placebo-controlled , Randomized , Double-blind , Double-dummy , Parallel group , Fixed dose design</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety DA-8031 Male Patients With Premature Ejaculation</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<criteria>Male patient age premature ejaculation 6 month . PEDT score ≥ 11 IIEFEF domain ≤ 21 Serum Creatinine ≥ 2.5 mg/dl AST , ALT &gt; 3*Upper limit normal Subjects hypotension ( SBP/DBP &lt; 90/50mmHg ) uncontrolled hypertension ( SBP/DBP &gt; 180/100mmHg ) Subjects chronic depression , psychiatric schizophrenia , Subjects alcohol , drug substance abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>